Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Growth in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 4,820,000 shares, an increase of 8.6% from the December 15th total of 4,440,000 shares. Currently, 19.6% of the shares of the company are sold short. Based on an average trading volume of 400,900 shares, the short-interest ratio is currently 12.0 days.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ARCT. nVerses Capital LLC purchased a new position in shares of Arcturus Therapeutics in the third quarter valued at $42,000. China Universal Asset Management Co. Ltd. grew its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at about $142,000. Point72 DIFC Ltd purchased a new stake in shares of Arcturus Therapeutics in the second quarter worth about $188,000. Finally, SG Americas Securities LLC bought a new position in shares of Arcturus Therapeutics in the third quarter valued at approximately $191,000. Institutional investors own 94.54% of the company’s stock.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright reissued a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $66.75.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $16.79 on Monday. The business’s fifty day moving average price is $17.46 and its 200-day moving average price is $19.83. Arcturus Therapeutics has a one year low of $14.30 and a one year high of $45.00. The stock has a market capitalization of $454.79 million, a PE ratio of -7.56 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter last year, the company earned ($0.61) earnings per share. As a group, equities analysts expect that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.